Short Interest in PAVmed Inc. (NASDAQ:PAVM) Declines By 23.4%

PAVmed Inc. (NASDAQ:PAVM) was the target of a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 99,245 shares, a drop of 23.4% from the January 29th total of 129,582 shares. Approximately 11.1% of the company’s shares are short sold. Based on an average daily trading volume, of 299,941 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 299,941 shares, the days-to-cover ratio is presently 0.3 days. Approximately 11.1% of the company’s shares are short sold.

PAVmed Stock Performance

NASDAQ PAVM traded down $0.25 on Monday, hitting $9.84. The stock had a trading volume of 5,886 shares, compared to its average volume of 1,550,647. The firm has a 50-day moving average of $8.98 and a 200-day moving average of $11.19. The company has a market capitalization of $9.68 million, a price-to-earnings ratio of -0.57 and a beta of 1.12. PAVmed has a 52-week low of $6.00 and a 52-week high of $28.44.

Analyst Ratings Changes

PAVM has been the topic of a number of analyst reports. Ascendiant Capital Markets dropped their price objective on PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of PAVmed to a “sell” rating in a research note on Saturday, February 14th. Finally, Zacks Research lowered shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $510.00.

Hedge Funds Weigh In On PAVmed

A hedge fund recently raised its stake in PAVmed stock. Jane Street Group LLC grew its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the quarter. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.